Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

被引:0
|
作者
Li, Qingsong [1 ,2 ,3 ]
Liang, Na [1 ,2 ,3 ]
Ouyang, Weiwei [1 ,2 ,3 ]
Su, Shengfa [1 ,2 ,3 ]
Ma, Zhu [1 ,2 ]
Geng, Yichao [1 ,2 ,3 ]
Hu, Yinxiang [1 ,2 ,3 ]
Li, Huiqin [1 ,2 ]
Lu, Bing [1 ,2 ,3 ]
机构
[1] Guizhou Med Univ, Affiliated Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Dept Thorac Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
[3] Guizhou Med Univ, Clin Med Coll, Teaching & Res Dept Oncol, 1 Beijing Rd West, Guiyang 550004, Peoples R China
关键词
Time; Non-small cell lung cancer (NSCLC); EGFR-TKIs; Primary tumor radiotherapy; Overall survival; TYROSINE KINASE INHIBITORS; OPEN-LABEL; PHASE-III; ADENOCARCINOMA HISTOLOGY; CONCURRENT CHEMOTHERAPY; MAINTENANCE THERAPY; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; RADIATION-THERAPY; GEFITINIB;
D O I
10.1186/s12885-024-12826-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. Patients and methods In total, 238 patients with EGFR-TKIs and OS >= 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it. The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R0 - 30(<30 days), R30 - PD(>= 30 days and disease stable), and R-PD(radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. Results The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3-33.7) for the R group and 22 months(95% CI: 20.4-23.6) for the D group (chi(2) = 13.480, p<0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS. Among the four groups, The R30 - PD appeared to have the best OS (D, chi(2) = 19.307, p<0.001;R0 - 30, chi(2) = 11.687, p = 0.01; R-PD, chi(2) = 4.086, p = 0.043). Landmark analyses(22 months) showed the R30 - PD group had a significant long-term OS. The incidence of radiation pneumonitis >= grade 2 was17.3%(n = 19)and radiation esophagitis >= grade 2 was observed in 32 patients(29.1%). Conclusions Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R30 - PD)of primary tumour radiotherapy may be the best choice. Premature radiotherapy(R0 - 30) and radiotherapy after disease progression (R-PD)may not be reasonable for long-term OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition
    Wang, Qi
    Li, Xuefei
    Ren, Shengxiang
    Su, Chunxia
    Li, Chunyu
    Li, Wei
    Yu, Jia
    Cheng, Ningning
    Zhou, Caicun
    LUNG CANCER, 2020, 147 : 99 - 105
  • [22] A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
    Cui, Ran
    Wei, Chun
    Li, Xianyi
    Jiang, Ou
    MEDICINE, 2022, 101 (47) : E31894
  • [23] Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
    Jia, Yijun
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Su, Chunxia
    Gao, Guanghui
    Li, Wei
    Zhou, Fei
    Li, Jiayu
    Zhou, Caicun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance
    Han, Ruoshuang
    Jia, Yijun
    Li, Xuefei
    Zhao, Chao
    Zhao, Sha
    Liu, Sangtian
    Liu, Yiwei
    Chen, Donglai
    Zhang, Qian
    Liu, Xiaozhen
    Shi, Jinpeng
    Li, Jiayu
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) : 1277 - 1291
  • [25] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
    Sheng, Zhixin
    Zhang, Yanxia
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 7
  • [26] SHOC2 Is a Critical Modulator of Sensitivity to EGFR-TKIs in Non-Small Cell Lung Cancer Cells
    Terai, Hideki
    Hamamoto, Junko
    Emoto, Katsura
    Masuda, Takeshi
    Manabe, Tadashi
    Kuronuma, Satoshi
    Kobayashi, Keigo
    Masuzawa, Keita
    Ikemura, Shinnosuke
    Nakayama, Sohei
    Kawada, Ichiro
    Suzuki, Yusuke
    Takeuchi, Osamu
    Suzuki, Yukio
    Ohtsuki, Sumio
    Yasuda, Hiroyuki
    Soejima, Kenzo
    Fukunaga, Koichi
    MOLECULAR CANCER RESEARCH, 2021, 19 (02) : 317 - 328
  • [27] Efficacy and safety of EGFR-TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
    Wang, Jia-li
    Chen, Chuan-sheng
    Jia, Zhi-rong
    Miao, Li-yun
    Xie, Jun
    Pan, Zhen-zhen
    Duan, Ya-lei
    Liu, Shuo
    Hou, Meng-jun
    Ding, Xuan-sheng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3895 - 3903
  • [28] The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
    Laface, Carmelo
    Maselli, Felicia Maria
    Santoro, Anna Natalizia
    Iaia, Maria Laura
    Ambrogio, Francesca
    Laterza, Marigia
    Guarini, Chiara
    De Santis, Pierluigi
    Perrone, Martina
    Fedele, Palma
    PHARMACEUTICS, 2023, 15 (06)
  • [29] Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer
    Byun, Joo-Young
    Han, Sola
    Qdaisat, Aiham
    Park, Chanhyun
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (08) : 1007 - 1015
  • [30] MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
    Li, Jiayu
    Li, Xuefei
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhang, Yishi
    Zhou, Fei
    Zhao, Mingchuan
    Zhao, Chao
    Chen, Xiu
    Cheng, Ningning
    Zhao, Yinmin
    Zhou, Caicun
    Hirsch, Fred R.
    ONCOTARGET, 2014, 5 (17) : 7902 - 7916